Roche

Career for Associate Scientific Services - Oncology (Avastin) in Roche | B.Pharm/B.Sc

At Roche, 80,000 people across 150 countries are pushing back the frontiers of healthcare. Working together, we’ve become one of the world’s leading research-focused healthcare groups. Our success is built on innovation, curiosity and diversity.
Roche Diagnostics India, with a sales turnover of INR 150 crores, nurtures an open, flexible and challenging work environment, which allows for rapid career progression. Favored by its geographic location in the heart of Europe, the Basel area is one of the most dynamic economic regions in Switzerland — a great place to live and work.

Post: Associate Scientific Services - Oncology (Avastin)

Roche and Upsher-Smith joined to develop novel VAP-1 Inhibitor

  • Posted on: 2 December 2015
  • By: Gayatri Mahajan

Upsher-Smith Laboratories, Inc. (Upsher-Smith), through its wholly-owned UK subsidiary Proximagen Ltd. joined with Roche for the further development of a novel, oral small molecule inhibitor of Vascular Adhesion Protein 1 (VAP-1), a cell-adhesion molecule that may be effective in the treatment of inflammatory diseases. The VAP-1 inhibitor is currently in phase II clinical development.

Roche launches new H&E tissue staining solution - the VENTANA HE 600 system

  • Posted on: 13 November 2015
  • By: Shalini.Sharma

Roche announced the launch of the VENTANA HE 600 system, the latest fully automated hematoxylin and eosin (H&E) tissue staining system that enhances patient and technician safety and produces exceptional staining quality.
The VENTANA HE 600 system delivers fresh reagents on each individual slide without relying on user-supplied alcohol and deionized (DI) water, resulting in improved consistency and quality in tissue staining. This individual slide staining technology mitigates the risk of specimen cross contamination that can occur with other technologies, helping to reduce patient misdiagnosis.

In India Roche introduces new treatments for metastatic breast cancer patients

  • Posted on: 16 October 2015
  • By: Shalini.Sharma

Roche Pharma India recently introduce  two innovative medicines for the treatment of HER2-positive metastatic breast cancer, a particularly aggressive form of the disease. The new drugs, Perjeta and Kadcyla, have been shown to both extend survival and improve quality of life in their approved applications for metastatic HER2-positive breast cancer.

Roche acquires Lumora’s heat elution technology

  • Posted on: 1 September 2015
  • By: Shalini.Sharma

Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical research and industrial markets, has sold its proprietary nucleic acid heat elution purification technology to Roche. Roche has signed a definitive asset purchase agreement with Lumora for products associated with its proprietary nucleic acid heat elution purification technology that is designed for use with clinical specimens.

Roche's investigational immunotherapy atezolizumab met endpoint in specific type of lung cancer

  • Posted on: 17 August 2015
  • By: PharmaTutor News

Roche announced that in the large pivotal Phase II study, BIRCH, the investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PDL1) met its primary endpoint and shrank tumours (objective response rate; ORR) in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease expressed PD-L1 (Programmed Death Ligand-1). The study showed the amount of PD-L1 expressed by a person’s cancer correlated with their response to the medicine. Adverse events were consistent with what has been previously observed for atezolizumab.

Amgen, Roche joined for study on cancer immunotherapy with talimogene laherparepvec & atezolizumab

  • Posted on: 9 June 2015
  • By: Shalini.Sharma

Amgen join with Roche on a phase 1b study to evaluate the safety and efficacy of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with Roche's investigational anti-PDL1 therapy, atezolizumab (also known as MPDL3280A), in patients with triple-negative breast cancer and colorectal cancer with liver metastases.

Vacancy as Zonal Manager - Oncology in Roche

At Roche, 80,000 people across 150 countries are pushing back the frontiers of healthcare. Working together, we’ve become one of the world’s leading research-focused healthcare groups. Our success is built on innovation, curiosity and diversity.
Roche Diagnostics India, with a sales turnover of INR 150 crores, nurtures an open, flexible and challenging work environment, which allows for rapid career progression. Favored by its geographic location in the heart of Europe, the Basel area is one of the most dynamic economic regions in Switzerland — a great place to live and work.

Post: Zonal Manager - Oncology (West)

Pages